Avanir's Nuedexta becomes first drug in US approved for pseudobulbar affect
This article was originally published in Scrip
Executive Summary
Avanir's Nuedexta (previously known as Zenvia) has become the first therapy specifically approved for pseudobulbar affect in the US. The company, which saw its share price more than double on the approval by the FDA, expects Nuedexta to be available by prescription during the first quarter of 2011.